RVPH 241220 7.50P (RVPH241220P7500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

RVPH241220P7500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 26 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

8-K: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights
SECNov 14 17:31 ET
Reviva Pharmaceuticals Reports Q3 EPS (25c), Consensus (25c)
TipRanksNov 14 17:30 ET
Reviva Pharmaceuticals Reports Progress on Brilaroxazine Trials and Financial Results for Q3 2024
Quiver QuantitativeNov 14 17:30 ET
Reviva Pharm Holdings 3Q Loss/Shr 25c >RVPH
Dow JonesNov 14 17:25 ET
Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital
Dow JonesNov 14 17:25 ET · Ratings
Reviva Pharm Holdings Price Target Maintained With a $15.00/Share by D. Boral Capital
Dow JonesNov 14 17:25 ET · Ratings

Comments

Clintzilla

Nov 12 12:22

$Reviva Pharmaceuticals (RVPH.US)$ well i gave this play out a while ago anyone knows me knows i know this ticker for past few years.. nice moves today, will read and catch up on it, volume light, market conditions not great but 40% pretty good day so far.. will be on radar next year as well

Clintzilla

Sep 13 12:00

$Reviva Pharmaceuticals (RVPH.US)$ primed for a big move soon

Jaguar8

Sep 9 07:02

NEWS

$Reviva Pharmaceuticals (RVPH.US)$
Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
– Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia –
– Additional vocal biomarker data from ongoing open label extension study evaluating brilaroxazine in schizophrenia expected Q4 2024 –
CUPERTINO, Calif., Sept. 09, 2024 (GLOB...

Jaguar8

Aug 27 07:08

NEWS

$Reviva Pharmaceuticals (RVPH.US)$
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024